Amneal Outlines Ambitions To Become Leading Affordable Medicines Supplier In US
American Business Sits At Around $1.5bn And Growing
While it currently sits in fourth place, Amneal’s co-CEO Chirag Patel has laid out ambitions for the firm to become the number one supplier of affordable medicines in the US.
You may also be interested in...
Amneal now expects an additional $50m in net revenue this year, revising its revenue expectations up to between $2.3bn and $2.4bn following a successful second quarter.
With its pure partnered approach, US-based player Amneal has tallied up its third biosimilar launch in the market.
With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.